Skip to main content
. 2018 Jul 25;3(5):e000332. doi: 10.1136/esmoopen-2018-000332

Figure 1.

Figure 1

PFS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients (n=34). mPFS, median progression-free survival; nr, not reached; PD-L1, programmed death-ligand 1; PFS, progression-free survival.